These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 1637784)

  • 1. Human leukocyte antigen expression in renal cell carcinoma lesions does not predict the response to interferon therapy.
    Mattijssen V; Van Moorselaar J; De Mulder PH; Schalkwijk L; Ruiter DJ
    J Immunother (1991); 1992 Jul; 12(1):64-9. PubMed ID: 1637784
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HLA-class-I and -class-II expression on renal tumor xenografts and the relation to sensitivity for alpha-IFN, gamma-IFN and TNF.
    Beniers AJ; Peelen WP; Debruyne FM; Schalken JA
    Int J Cancer; 1991 Jul; 48(5):709-16. PubMed ID: 1906431
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized phase II trial comparing two different sequence combinations of autologous vaccine and human recombinant interferon gamma and human recombinant interferon alpha2B therapy in patients with metastatic renal cell carcinoma: clinical outcome and analysis of immunological parameters.
    Schwaab T; Heaney JA; Schned AR; Harris RD; Cole BF; Noelle RJ; Phillips DM; Stempkowski L; Ernstoff MS
    J Urol; 2000 Apr; 163(4):1322-7. PubMed ID: 10737537
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunohistochemical correlates of response to recombinant interleukin-2-based immunotherapy in humans.
    Rubin JT; Elwood LJ; Rosenberg SA; Lotze MT
    Cancer Res; 1989 Dec; 49(24 Pt 1):7086-92. PubMed ID: 2582450
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of the expression of HLA class I, proinflammatory cytokines and chemokines in primary tumors from patients with localized and metastatic renal cell carcinoma.
    Romero JM; Aptsiauri N; Vazquez F; Cozar JM; Canton J; Cabrera T; Tallada M; Garrido F; Ruiz-Cabello F
    Tissue Antigens; 2006 Oct; 68(4):303-10. PubMed ID: 17026465
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Major histocompatibility complex class I and class II expression in renal cell carcinoma and modulation by interferon gamma.
    Gastl G; Ebert T; Finstad CL; Sheinfeld J; Gomahr A; Aulitzky W; Bander NH
    J Urol; 1996 Jan; 155(1):361-7. PubMed ID: 7490887
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Growth and major histocompatibility antigen expression regulation by IL-4, interferon-gamma (IFN-gamma) and tumour necrosis factor-alpha (TNF-alpha) on human renal cell carcinoma.
    Hillman GG; Puri RK; Kukuruga MA; Pontes JE; Haas GP
    Clin Exp Immunol; 1994 Jun; 96(3):476-83. PubMed ID: 8004818
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of HLA-G for protection of human renal cell-carcinoma cells from immune-mediated lysis: implications for immunotherapies.
    Bukur J; Seliger B
    Semin Cancer Biol; 2003 Oct; 13(5):353-9. PubMed ID: 14708715
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Altered expression of nonclassical HLA class Ib antigens in human renal cell carcinoma and its association with impaired immune response.
    Bukur J; Malenica B; Huber C; Seliger B
    Hum Immunol; 2003 Nov; 64(11):1081-92. PubMed ID: 14602239
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Major histocompatibility complex class II antigens on renal cell cancer--immunohistochemical study and effect on their expression by interferon].
    Tomita Y
    Nihon Hinyokika Gakkai Zasshi; 1990 Jul; 81(7):1079-86. PubMed ID: 2120500
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HLA class I expression predicts prognosis and therapeutic benefits from tyrosine kinase inhibitors in metastatic renal-cell carcinoma patients.
    Wang J; Liu L; Qu Y; Xi W; Xia Y; Bai Q; Xiong Y; Long Q; Xu J; Guo J
    Cancer Immunol Immunother; 2018 Jan; 67(1):79-87. PubMed ID: 28918459
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HLA phenotype and cytokine-induced tumor control in advanced renal cell cancer.
    Franzke A; Buer J; Probst-Kepper M; Lindig C; Framzle M; Schrader AJ; Ganser A; Atzpodien J
    Cancer Biother Radiopharm; 2001 Oct; 16(5):401-9. PubMed ID: 11776757
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor infiltrating dendritic cells predict treatment response to immmunotherapy in patients with metastatic renal cell carcinoma.
    Kobayashi M; Suzuki K; Yashi M; Yuzawa M; Takayashiki N; Morita T
    Anticancer Res; 2007; 27(2):1137-41. PubMed ID: 17465253
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of HLA-G expression in renal cell carcinoma.
    Li BL; Lin A; Zhang XJ; Zhang X; Zhang JG; Wang Q; Zhou WJ; Chen HX; Wang TJ; Yan WH
    Tissue Antigens; 2009 Sep; 74(3):213-21. PubMed ID: 19531101
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Functional role of human leukocyte antigen-G up-regulation in renal cell carcinoma.
    Bukur J; Rebmann V; Grosse-Wilde H; Luboldt H; Ruebben H; Drexler I; Sutter G; Huber C; Seliger B
    Cancer Res; 2003 Jul; 63(14):4107-11. PubMed ID: 12874014
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression pattern of HLA class I antigens in renal cell carcinoma and primary cell line cultures: methodological implications for immunotherapy.
    Hanak L; Slaby O; Lauerova L; Kren L; Nenutil R; Michalek J
    Med Sci Monit; 2009 Dec; 15(12):CR638-43. PubMed ID: 19946235
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunological effects of treatment with sequential administration of recombinant interferon gamma and alpha in patients with metastatic renal cell carcinoma during a phase I trial.
    Ernstoff MS; Gooding W; Nair S; Bahnson RR; Miketic LM; Banner B; Day R; Whiteside T; Titus-Ernstoff L; Kirkwood JM
    Cancer Res; 1992 Feb; 52(4):851-6. PubMed ID: 1737346
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor-specific up-regulation of the nonclassical class I HLA-G antigen expression in renal carcinoma.
    Ibrahim EC; Guerra N; Lacombe MJ; Angevin E; Chouaib S; Carosella ED; Caignard A; Paul P
    Cancer Res; 2001 Sep; 61(18):6838-45. PubMed ID: 11559559
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Classes I and II HLA and melanoma-associated antigen expression and modulation on melanoma cells isolated from primary and metastatic lesions.
    Taramelli D; Fossati G; Mazzocchi A; Delia D; Ferrone S; Parmiani G
    Cancer Res; 1986 Jan; 46(1):433-9. PubMed ID: 3079589
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HLA-G as a target molecule in specific immunotherapy against renal cell carcinoma.
    Komohara Y; Harada M; Ishihara Y; Suekane S; Noguchi M; Yamada A; Matsuoka K; Itoh K
    Oncol Rep; 2007 Dec; 18(6):1463-8. PubMed ID: 17982631
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.